Provided by Tiger Fintech (Singapore) Pte. Ltd.

4D Molecular Therapeutics

2.91
-0.3750-11.43%
Volume:299.45K
Turnover:893.50K
Market Cap:134.51M
PE:-0.97
High:3.12
Open:3.12
Low:2.90
Close:3.28
Loading ...

4D Molecular Therapeutics FY 2024 GAAP EPS $(2.98) Misses $(2.92) Estimate, Sales $37.000K

Benzinga
·
01 Mar

Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating

MT Newswires Live
·
11 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Globus Medical (GMED) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

4D Molecular price target lowered to $30 from $39 at Chardan

TIPRANKS
·
11 Feb

Chardan Capital Keeps Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
11 Feb

4D Molecular Therapeutics (FDMT) Gets a Buy from RBC Capital

TIPRANKS
·
11 Feb

4D Molecular’s wAMD drug is best-in-class, says RBC, sees ‘ideal’ entry point

TIPRANKS
·
11 Feb

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

GlobeNewswire
·
29 Jan

H.C. Wainwright Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
22 Jan

BUZZ-BMO downgrades 4D Molecular Therapeutics to 'market perform' on durability concerns

Reuters
·
14 Jan

BMO Capital Downgrades 4D Molecular Therapeutics to Market Perform From Outperform, Adjusts Price Target to $15 From $40

MT Newswires Live
·
13 Jan

4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Jan

4D Molecular Therapeutics Inc : Bmo Cuts to Market Perform From Outperform

THOMSON REUTERS
·
13 Jan

Promising Interim Results Drive ‘Buy’ Rating for 4D Molecular Therapeutics

TIPRANKS
·
13 Jan

Barclays Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
12 Jan

4D Molecular price target lowered to $42 from $46 at BofA

TIPRANKS
·
12 Jan

Cautious Outlook for 4D Molecular Therapeutics Amid Competitive Challenges and Safety Concerns

TIPRANKS
·
11 Jan

Buy Rating Reiterated for 4D Molecular Therapeutics Amid Strategic Advancements and Undervalued Commercial Prospects

TIPRANKS
·
11 Jan

Cautious Outlook for 4D Molecular Therapeutics Amid Limited Therapy Durability and Competitive Pressures

TIPRANKS
·
11 Jan